What This Article Covers
This article summarizes published research on IGF1-LR3 for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.
- The evidence set is driven by animal, in vitro, and tissue-engineering studies; it does not include human clinical outcome trials for LR3 IGF-1 or native IGF-1. The evidence set explicitly advises against broad human-efficacy framing.
- Several findings concern native IGF-1 rather than LR3 IGF-1; results are context-dependent across analogue, species, route, and delivery format.
Bottom Line
- Direct human efficacy or safety evidence for IGF1-LR3 is absent in this evidence set.
- Preclinical studies report heterogeneous, model-specific effects for LR3 IGF-1 and/or native IGF-1 across growth, metabolism, neuropathology markers, and nerve repair, with outcomes varying by analogue, species, age, route, and delivery construct.
- Mechanistic and structural work supports biological plausibility but does not establish clinical utility. Dosing or safety conclusions for humans are not supported by the evidence set.
What Was Tested in Humans?
No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.
What Did Animal and Mechanistic Studies Show?
The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.
How the Evidence Fits Together
The practical reading for IGF1-LR3 is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.
What Is Not Established
- Broad human efficacy for IGF1-LR3 is not established by this article.
- Animal, cellular, or review-level findings should not be converted into human-use claims.
- Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.
Research-Use Boundary
This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.
Selected Sources
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. https://pubmed.ncbi.nlm.nih.gov/39679943/
- Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. https://pubmed.ncbi.nlm.nih.gov/39610283/
- Decellularized Alstroemeria stem-based nerve conduit with GelMA and controlled IGF-1 LR3 release for rat sciatic nerve regeneration. https://pubmed.ncbi.nlm.nih.gov/41015370/
- Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. https://pubmed.ncbi.nlm.nih.gov/10370861/
- IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus. https://pubmed.ncbi.nlm.nih.gov/33427051/
- Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. https://pubmed.ncbi.nlm.nih.gov/33938236/
- Preferential intestinal delivery of long[Arg3] IGF-1 over IGF-1 in preweaning and adult rats. https://pubmed.ncbi.nlm.nih.gov/12697696/
- Systemically but not orogastrically delivered IGF-1 and long [Arg3] IGF-1 stimulate intestinal disaccharidase activity in suckling rats. https://pubmed.ncbi.nlm.nih.gov/9803447/
- N-Linked glycosylation in CHO cells is critical for IGF-1 signaling. https://pubmed.ncbi.nlm.nih.gov/36499281/
- IGF-1/IGFBPs in proliferation and differentiation of murine bone marrow–derived macrophage precursors. https://pubmed.ncbi.nlm.nih.gov/9867252/
- Systemic infusion of IGF-1 or LR3 IGF-1 stimulates visceral organ growth and gut proliferation in suckling rats. https://pubmed.ncbi.nlm.nih.gov/9124573/
- Solution structure and backbone dynamics of long-[Arg(3)] insulin-like growth factor-I. https://pubmed.ncbi.nlm.nih.gov/10744677/
- LR3 IGF-1 enhances superovulatory response in rats (journal report). https://doi.org/10.1016/S0015-0282(97)84896-0
- LR3 IGF-1 enhances superovulatory response in rats (conference abstract). https://doi.org/10.1016/S0015-0282(97)90811-6
- Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. https://doi.org/10.1007/s00253-023-12606-0
- Physicochemical characteristics of LR3-IGF1 protein inclusion bodies. https://doi.org/10.1021/bp010058x
- Detection of His-tagged Long-R3-IGF-I in a black market product. https://doi.org/10.1016/j.ghir.2010.07.001
Related KRL Resources
Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.
1st Time Customers Receive 10% off their 1st order over $100.00 with CODE KRL10
Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.